In the process of a CRISPR/Cas9 genome editing screen in B16.SIY melanoma cells to discover gene alterations mediating resistance to CD8+ T cell killing in vitro, we confirmed the importance of IFNγR signaling on tumor cells in this process. The gene discussed is CD8A; the disease is melanoma.